LIVN

As of 2026-10-26, LIVN scores 46out of 100 on QNTM’s five-factor quantitative model, a moderate conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. LIVN trades at $80.62, within its fair-value band.

LIVN scores 46 out of 100 on QNTM's five-factor model — a moderate reading — neither strongly favored nor flagged for weakness at 46. Its strongest factor is value at 60 (solid), where it screens cheap on the model's valuation inputs, followed by momentum at 52. The weakest is sentiment at 29, where sentiment signals are working against it. Among Healthcare stocks it sits in the lower 36% of Healthcare names by composite.

On valuation, LIVN is priced in the lower part of its recent range. The blended composite before the macro overlay was 47. Same-sector names the model rates nearby include HALO, VEEV, THC.

This is a descriptive factor read on LIVN, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where LIVN sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for LIVN runs $68.84–$101.22. Current price $80.62 sits within its fair-value band. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-10-26.